REVENUE (Tables)

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue from contracts with customers

The following table summarizes revenue from contracts with customers for the three months ended March 31, 2019 and 2018 (in thousands):

	Three Months Ended March 31,
	2019		2018
Product sales, net
Gralise	$	13,278	$	14,827
CAMBIA	8,808		6,416
Zipsor	4,231		4,746
Total neurology product sales, net	26,317		25,989
NUCYNTA products	62		18,145
Lazanda	71		220
Total product sales, net	26,450		44,354
Commercialization agreement:
Commercialization rights and facilitation services, net	30,856		28,095
Revenue from transfer of inventory	—		55,705
Royalties and milestone revenue	623		250
Total revenues	$	57,929	$	128,404

Summary of contract assets and liabilities

The following table presents changes in the Company’s contract assets and liabilities for the three months ended March 31, 2019 (in thousands):

	Balance as of							Balance as of
	December 31, 2018		Additions		Deductions			March 31, 2019
Contract assets:
Contract asset - Cambia Canada	$	—	$	300	$	—		$	300
Contract asset - Collegium	2,416		—		(199		)	2,217
	$	2,416	$	300	$	(199	)	$	2,517